C60-fullerenes for delivery of docetaxel to breast cancer cells: A promising approach for enhanced efficacy and better pharmacokinetic profile.

Docetaxel has always attracted the researchers owing to its promises and challenges. Despite marked efficacy, concerns like poor aqueous solubility, lower bioavailability, poor tissue penetration and dose related side-effects offer further scope of research on docetaxel. The present study aims to explore the potential of C60-fullerenes in the delivery of docetaxel to cancerous cells. C60-fullerenes were carboxylated, acylated and conjugated with the drug. The chemical processes were monitored by UV, FT-IR and NMR spectroscopy. The conjugate was further characterized for drug loading, micromeritics, drug release, morphology and evaluated for in-vitro cytotoxicity, haemolysis and in-vivo pharmacokinetic profile. The developed nanoconstruct was able to enhance the bioavailability of docetaxel by 4.2 times and decrease the drug clearance by 50%. The developed system was able to control the drug release and was found to be compatible with erythrocytes. The cytotoxic potential on studied MCF-7 and MDA-MB231 cell lines was also enhanced by many folds, indicating marked promise in efficacy enhancement and dose reduction. The present findings are encouraging and offer a technique to enhance the delivery and efficacy potential of anticancer agents, especially belonging to BCS class IV.

[1]  K. Yap,et al.  Characterization of the 13-cis-retinoic acid/cyclodextrin inclusion complexes by phase solubility, photostability, physicochemical and computational analysis. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  Kinam Park,et al.  Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[3]  A. Trpković,et al.  Toxicity of pristine versus functionalized fullerenes: mechanisms of cell damage and the role of oxidative stress , 2012, Archives of Toxicology.

[4]  W. Chung,et al.  The Syntheses of Pyrazino-Containing Sultines and Their Application in Diels—Alder Reactions with Electron-Poor Olefins and [60]Fullerene. , 2000 .

[5]  Robert J. Gillies,et al.  Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells , 2005, Molecular Cancer Therapeutics.

[6]  Yoshimune Nonomura,et al.  Non-Engineered Nanoparticles of C60 , 2013, Scientific Reports.

[7]  Maxim Evstigneev,et al.  C60 Fullerene as Synergistic Agent in Tumor-Inhibitory Doxorubicin Treatment , 2014, Drugs in R&D.

[8]  Min Li,et al.  Synergistic enhancement of cancer therapy using a combination of docetaxel and photothermal ablation induced by single-walled carbon nanotubes , 2011, International journal of nanomedicine.

[9]  R F Schinazi,et al.  Synthesis and virucidal activity of a water-soluble, configurationally stable, derivatized C60 fullerene , 1993, Antimicrobial Agents and Chemotherapy.

[10]  Michael R Hamblin,et al.  Photodynamic therapy with fullerenes , 2007, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[11]  F. Albericio,et al.  Morphological characterization of fullerene–androsterone conjugates , 2014, Beilstein journal of nanotechnology.

[12]  Z. Gu,et al.  Solubility of Fullerene C60 and C70 in Toluene, o-Xylene and Carbon Disulfide at Various Temperatures , 1997 .

[13]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[14]  Jia-You Fang,et al.  Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion , 2008, Acta Pharmacologica Sinica.

[15]  Inderpreet Kaur,et al.  Attachment of Docetaxel to Multiwalled Carbon Nanotubes for Drug Delivery Applications , 2012 .

[16]  Z. Marković,et al.  Biomedical potential of the reactive oxygen species generation and quenching by fullerenes (C60). , 2008, Biomaterials.

[17]  Shinobu Ito,et al.  Preclinical studies on safety of fullerene upon acute oral administration and evaluation for no mutagenesis. , 2006, Toxicology.

[18]  P. R. Sharma,et al.  Tiron and trolox potentiate the autophagic cell death induced by magnolol analog Ery5 by activation of Bax in HL-60 cells , 2013, Apoptosis.

[19]  K. Tkaczuk,et al.  Update on taxane development: new analogs and new formulations , 2012, Drug design, development and therapy.

[20]  P. R. Kumar,et al.  A stability-indicating HPLC assay method for docetaxel. , 2006, Journal of pharmaceutical and biomedical analysis.

[21]  J. Schellens,et al.  Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). , 2011, International journal of pharmaceutics.

[22]  Jun Gao,et al.  PEGylated fullerene/iron oxide nanocomposites for photodynamic therapy, targeted drug delivery and MR imaging. , 2013, Biomaterials.

[23]  Michael O'Leary,et al.  Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. , 2004, The oncologist.

[24]  L. Bharadwaj,et al.  In Vitro Cytotoxicity of Multiwalled and Single-Walled Carbon Nanotubes on Human Cell Lines , 2015 .

[25]  Roy S Herbst,et al.  Mode of action of docetaxel - a basis for combination with novel anticancer agents. , 2003, Cancer treatment reviews.

[26]  J. Hainsworth,et al.  A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer. , 2008, Clinical breast cancer.

[27]  M. Gohel,et al.  Goodness-of-Fit Model-Dependent Approach for Release Kinetics of Levofloxacin Hemihydrates Floating Tablet , 2009 .

[28]  R. Govindan,et al.  Novel formulations of taxanes: a review. Old wine in a new bottle? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Philip R. Cohen,et al.  The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). , 1993, Cancer treatment reviews.

[30]  Y. Bae,et al.  Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells , 2012, Biochemistry research international.

[31]  Shinobu Ito,et al.  Safety evaluation of highly purified fullerenes (HPFs): based on screening of eye and skin damage. , 2009, The Journal of toxicological sciences.

[32]  S. Bhushan,et al.  An investigation of in vitro cytotoxicity and apoptotic potential of aromatic diselenides. , 2014, Bioorganic & medicinal chemistry letters.

[33]  Y. Kuo,et al.  Targeting delivery of saquinavir to the brain using 83-14 monoclonal antibody-grafted solid lipid nanoparticles. , 2013, Biomaterials.

[34]  J. Schellens,et al.  Modulation of oral bioavailability of anticancer drugs: from mouse to man. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[35]  L. Bharadwaj,et al.  Translocation and toxicity of docetaxel multi-walled carbon nanotube conjugates in mammalian breast cancer cells. , 2014, Journal of biomedical nanotechnology.

[36]  P. Potier.  Synthesis of the Antitumor Dimeric Indole Alkaloids From Catharanthus Species (Vinblastine Group) , 1980 .

[37]  A. Garshev,et al.  Study of Fullerene Aqueous Dispersion Prepared by Novel Dialysis Method: Simple Way to Fullerene Aqueous Solution , 2015 .

[38]  Zahra Badri,et al.  A theoretical survey on the D7d (84)fullerene, a fullerene with two heptagon rings , 2013 .

[39]  Lin Hou,et al.  PEI-derivatized fullerene drug delivery using folate as a homing device targeting to tumor. , 2013, Biomaterials.

[40]  Jung Hyun Kim,et al.  Preparation of thermally denatured albumin gel and its pH-sensitive swelling , 1998 .